Maria Stamelou

List of Publications by Year
in descending order

159 papers	10,762 citations	41344 49 h-index	40979 93 g-index
162 all docs	162 docs citations	162 times ranked	9809 citing authors

#	Article	IF	Citations
1	Plasma Glutathione and Prodromal Parkinson's Disease Probability. Movement Disorders, 2022, 37, 200-205.	3.9	10
2	Dietary Inflammatory Index score and prodromal Parkinson's disease incidence: The HELIAD study. Journal of Nutritional Biochemistry, 2022, 105, 108994.	4.2	6
3	Asymptomatic carriers of the p.A53T SNCA mutation: Data from the PPMI study. Parkinsonism and Related Disorders, 2022, 98, 72-74.	2.2	0
4	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. Movement Disorders, 2022, 37, 1131-1148.	3.9	222
5	Frailty and Prodromal Parkinsonâ€™s Disease: Results From the HELIAD Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 622-629.	3.6	16
6	REM sleep behavior disorder and other sleep abnormalities in p. A53T SNCA mutation carriers. Sleep, 2021, 44, .	1.1	6
7	The â€œzig-zagâ€•sign in progressive supranuclear palsy â€“ The slowness of vertical saccades was the clue. Parkinsonism and Related Disorders, 2021, 83, 6-7.	2.2	0
8	Expanding the Spectrum of <scp>AP5Z1â€</scp>Related Hereditary Spastic Paraplegia (<scp>HSPâ€SPG48</scp>): A Multicenter Study on a Rare Disease. Movement Disorders, 2021, 36, 1034-1038.	3.9	9
9	Genotypeâ€“Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review. Movement Disorders, 2021, 36, 1499-1510.	3.9	22
10	Serum uric acid level as a putative biomarker in Parkinson's disease patients carrying GBA1 mutations: 2-Year data from the PPMI study. Parkinsonism and Related Disorders, 2021, 84, 1-4.	2.2	9
11	Worldwide barriers to genetic testing for movement disorders. European Journal of Neurology, 2021, 28, 1901-1909.	3.3	21
12	Serum Uric Acid in LRRK2 Related Parkinsonâ€™s Disease: Longitudinal Data from the PPMI Study. Journal of Parkinson's Disease, 2021, 11, 633-640.	2.8	3
13	Late life psychotic features in prodromal Parkinson's disease. Parkinsonism and Related Disorders, 2021, 86, 67-73.	2.2	5
14	Childhoodâ€Onset Chorea Caused by a Recurrent De Novo DRD2 Variant. Movement Disorders, 2021, 36, 1472-1473.	3.9	6
15	Commentary: Insulinomaâ€Induced Hypoglycemia with Generalized Chorea, Dystonia, and Ataxia: A Neurological Kaleidoscope. Movement Disorders Clinical Practice, 2021, 8, S9-S10.	1.5	0
16	Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies. Nature Reviews Neurology, 2021, 17, 601-620.	10.1	41
17	Apathy: An underestimated feature in GBA and LRRK2 non-manifesting mutation carriers. Parkinsonism and Related Disorders, 2021, 91, 1-8.	2.2	8
18	A Modified Progressive Supranuclear Palsy Rating Scale. Movement Disorders, 2021, 36, 1203-1215.	3.9	13

#	Article	IF	Citations
19	Association of the Polygenic Risk Score With the Probability of Prodromal Parkinsonâ€™s Disease in Older Adults. Frontiers in Molecular Neuroscience, 2021, 14, 739571.	2.9	6
20	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. Movement Disorders, 2020, 35, 171-176.	3.9	37
21	Circulating Brainâ€Enriched MicroRNAs for Detection and Discrimination of Idiopathic and Genetic Parkinson's Disease. Movement Disorders, 2020, 35, 457-467.	3.9	43
22	Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. Parkinsonism and Related Disorders, 2020, 78, 200-203.	2.2	8
23	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the <scp>Movement Disorder Society</scp> Multiple System Atrophy Study Group. Movement Disorders Clinical Practice, 2020, 7, 750-762.	1.5	31
24	Clinical Conditions â€œSuggestive of Progressive Supranuclear Palsyâ€â€”Diagnostic Performance. Movement Disorders, 2020, 35, 2301-2313.	3.9	22
25	Isolated and combined genetic tremor syndromes: a critical appraisal based on the 2018 MDS criteria. Parkinsonism and Related Disorders, 2020, 77, 121-140.	2.2	13
26	A Prospective Validation of the Updated Movement Disorders Society Research Criteria for Prodromal Parkinson's Disease. Movement Disorders, 2020, 35, 1802-1809.	3.9	15
27	DaTSCAN (123I-FP-CIT SPECT) imaging in early versus mid and late onset Parkinson's disease: Longitudinal data from the PPMI study. Parkinsonism and Related Disorders, 2020, 77, 36-42.	2.2	5
28	The Progressive Supranuclear Palsy Clinical Deficits Scale. Movement Disorders, 2020, 35, 650-661.	3.9	31
29	The different syndromes in Parkinson's disease: an overview. , 2020, , 235-249.		0
30	<scp>LRP1</scp>: A Novel Mediator of Tau Uptake. Movement Disorders, 2020, 35, 1136-1136.	3.9	1
31	Tremor in motor neuron disease may be central rather than peripheral in origin. European Journal of Neurology, 2019, 26, 394.	3.3	5
32	Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy. Movement Disorders, 2019, 34, 1087-1088.	3.9	2
33	Motor function and the probability of prodromal Parkinson's disease in older adults. Movement Disorders, 2019, 34, 1345-1353.	3.9	16
34	One decade ago, one decade ahead in progressive supranuclear palsy. Movement Disorders, 2019, 34, 1284-1293.	3.9	12
35	Neuroprotection in multiple system atrophy: unresolved issues. Lancet Neurology, The, 2019, 18, 710-711.	10.2	0
36	The relationship between environmental factors and different Parkinson's disease subtypes in Greece: Data analysis of the Hellenic Biobank of Parkinson's disease. Parkinsonism and Related Disorders, 2019, 67, 105-112.	2.2	21

#	Article	IF	Citations
37	Serotonergic pathology and disease burden in the premotor and motor phase of A53T Î±-synuclein parkinsonism: a cross-sectional study. Lancet Neurology, The, 2019, 18, 748-759.	10.2	70
38	Emerging drugs for progressive supranuclear palsy. Expert Opinion on Emerging Drugs, 2019, 24, 83-92.	2.4	6
39	A critique of the second consensus criteria for multiple system atrophy. Movement Disorders, 2019, 34, 975-984.	3.9	73
40	Mitochondrial complex I NUBPL mutations cause combined dystonia with bilateral striatal necrosis and cerebellar atrophy. European Journal of Neurology, 2019, 26, 1240-1243.	3.3	9
41	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders, 2019, 34, 1228-1232.	3.9	93
42	Autophagy dysfunction in peripheral blood mononuclear cells of Parkinsonâ€™s disease patients. Neuroscience Letters, 2019, 704, 112-115.	2.1	21
43	A special issue on childhoodâ€onset movement disorders. Movement Disorders, 2019, 34, 595-597.	3.9	1
44	Higher probability of prodromal Parkinson disease is related to lower cognitive performance. Neurology, 2019, 92, e2261-e2272.	1.1	34
45	How to approach a patient with parkinsonism â€“ red flags for atypical parkinsonism. International Review of Neurobiology, 2019, 149, 1-34.	2.0	4
46	Classification of atypical parkinsonism per pathology versus phenotype. International Review of Neurobiology, 2019, 149, 37-47.	2.0	10
47	Genetic mimics of the non-genetic atypical parkinsonian disorders â€“ the â€˜atypicalâ€™ atypical. International Review of Neurobiology, 2019, 149, 327-351.	2.0	8
48	Progressive supranuclear palsy. International Review of Neurobiology, 2019, 149, 49-86.	2.0	19
49	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism and Related Disorders, 2019, 60, 138-145.	2.2	7
50	Frontotemporal dementia spectrum: first genetic screen in a Greek cohort. Neurobiology of Aging, 2019, 75, 224.e1-224.e8.	3.1	16
51	Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease. Movement Disorders, 2019, 34, 48-57.	3.9	134
52	Phenotypic Characteristics in GBA-Associated Parkinsonâ€™s Disease: A Study in a Greek Population. Journal of Parkinson's Disease, 2018, 8, 101-105.	2.8	18
53	Progressive spasticity, supranuclear gaze palsy and postural instability, without parkinsonism: whatâ€™s in a phenotype?. Journal of the Neurological Sciences, 2018, 390, 84-86.	0.6	1
54	Intrafamilial variability in a polish family harbouring a frameshift THAP1 mutation. Journal of the Neurological Sciences, 2018, 388, 158.	0.6	0

#	Article	IF	Citations
55	Selective cognitive impairment and hyposmia in p.A53T SNCA PD vs typical PD. Neurology, 2018, 90, e864-e869.	1.1	28
56	Treatable inherited rare movement disorders. Movement Disorders, 2018, 33, 21-35.	3.9	79
57	Consensus Statement on the classification of tremors. from the task force on tremor of the International Parkinson and Movement Disorder Society. Movement Disorders, 2018, 33, 75-87.	3.9	918
58	Alpha-synuclein dimerization in erythrocytes of patients with genetic and non-genetic forms of Parkinsonâ€™s Disease. Neuroscience Letters, 2018, 672, 145-149.	2.1	35
59	The Parkinson's progression markers initiative (PPMI) â€“ establishing a PD biomarker cohort. Annals of Clinical and Translational Neurology, 2018, 5, 1460-1477.	3.7	330
60	123Iâ€FPâ€CIT SPECT [(123) Iâ€2Î²â€carbomethoxyâ€3Î²â€(4â€iodophenyl)â€Nâ€(3â€fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T Î±â€synuclein Parkinson's disease cohort versus Parkinson's disease. Movement Disorders, 2018, 33, 1734-1739.	3.9	9
61	Therapeutic Management of the Overlapping Syndromes of Atypical Parkinsonism. CNS Drugs, 2018, 32, 827-837.	5.9	16
62	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. Parkinsonism and Related Disorders, 2018, 56, 33-40.	2.2	17
63	Is increased spinal nociception another hallmark for Parkinsonâ€™s disease?. Journal of Neurology, 2017, 264, 570-575.	3.6	9
64	Manual MRI morphometry in Parkinsonian syndromes. Movement Disorders, 2017, 32, 778-782.	3.9	67
65	The Motor Syndrome of Parkinson's Disease. International Review of Neurobiology, 2017, 132, 25-32.	2.0	23
66	Advances in the Clinical Differential Diagnosis of Parkinson's Disease. International Review of Neurobiology, 2017, 132, 79-127.	2.0	4
67	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	3.9	121
68	Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. Movement Disorders, 2017, 32, 955-971.	3.9	179
69	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	3.9	1,402
70	Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials. Movement Disorders, 2017, 32, 842-852.	3.9	52
71	ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients. Parkinsonism and Related Disorders, 2017, 41, 37-43.	2.2	67
72	TMEM230: How does it fit in the etiology and pathogenesis of Parkinson's disease?. Movement Disorders, 2017, 32, 1159-1162.	3.9	13

#	Article	IF	Citations
73	Frontotemporal dementia as the presenting phenotype of p.A53T mutation carriers in the alpha-synuclein gene. Parkinsonism and Related Disorders, 2017, 35, 82-87.	2.2	27
74	â€œAtypicalâ€•atypical parkinsonism: Critical appraisal of a cohort. Parkinsonism and Related Disorders, 2017, 37, 36-42.	2.2	12
75	Clinical rating scale for pantothenate kinaseâ€associated neurodegeneration: A pilot study. Movement Disorders, 2017, 32, 1620-1630.	3.9	18
76	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Movement Disorders, 2017, 32, 1264-1310.	3.9	608
77	Nonmotor Features in Atypical Parkinsonism. International Review of Neurobiology, 2017, 134, 1285-1301.	2.0	21
78	Transducer-based evaluation of tremor. Movement Disorders, 2016, 31, 1327-1336.	3.9	64
79	Motor and Nonmotor Features of Carriers of the p.A53T Alphaâ€Synuclein Mutation: A Longitudinal Study. Movement Disorders, 2016, 31, 1226-1230.	3.9	134
80	Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes. European Journal of Neurology, 2016, 23, 772-779.	3.3	12
81	Atypical parkinsonism â€“ new advances. Current Opinion in Neurology, 2016, 29, 480-485.	3.6	16
82	A Review of Treatment Options for Progressive Supranuclear Palsy. CNS Drugs, 2016, 30, 629-636.	5.9	36
83	The Discovery of Central Nervous System Lymphatic Vessels: The Missing Link That Closes the Circle of Brain Immunosurveillance. Movement Disorders Clinical Practice, 2016, 3, 29-30.	1.5	1
84	Lateâ€onset cerebellar ataxia: Do not forget Friedreich's. Movement Disorders, 2016, 31, 7-8.	3.9	3
85	Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification. Movement Disorders, 2016, 31, 1506-1517.	3.9	120
86	Experimental pain sensitivity in multiple system atrophy and Parkinson's disease at an early stage. European Journal of Pain, 2016, 20, 1223-1228.	2.8	15
87	Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. Movement Disorders, 2016, 31, 742-747.	3.9	29
88	What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 319-323.	1.9	186
89	The clinical syndrome of dystonia with anarthria/aphonia. Parkinsonism and Related Disorders, 2016, 24, 20-27.	2.2	10
90	Lower urinary tract dysfunction in patients with functional movement disorders. Journal of the Neurological Sciences, 2016, 361, 192-194.	0.6	12

#	Article	IF	Citations
91	Interventions in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2016, 22, S93-S95.	2.2	14
92	Multiple system atrophy-mimicking conditions: Diagnostic challenges. Parkinsonism and Related Disorders, 2016, 22, S12-S15.	2.2	28
93	Pain in Parkinson's Disease: Current Concepts and a New Diagnostic Algorithm. Movement Disorders Clinical Practice, 2015, 2, 357-364.	1.5	39
94	Lysosomal alterations in peripheral blood mononuclear cells of Parkinson's disease patients. Movement Disorders, 2015, 30, 1830-1834.	3.9	53
95	Levodopaâ€Responsive Parkinsonism with Prominent Freezing and Abnormal <scp>Dopamine Transporter</scp> Scan Associated with <scp>SANDO</scp> Syndrome. Movement Disorders Clinical Practice, 2015, 2, 304-307.	1.5	7
96	Nonmotor Symptoms in Dopaâ€Responsive Dystonia. Movement Disorders Clinical Practice, 2015, 2, 347-356.	1.5	10
97	From a single nucleotide polymorphism to tau pathology: Appoptosin is the missing link. Movement Disorders, 2015, 30, 1871-1872.	3.9	2
98	Hâ€ABC syndrome and DYT4: Variable expressivity or pleiotropy of TUBB4 mutations?. Movement Disorders, 2015, 30, 828-833.	3.9	117
99	Diseaseâ€Modifying Treatments for Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2015, 2, 3-5.	1.5	6
100	Clinical relevance of serum antibodies to extracellularN-methyl-d-aspartate receptor epitopes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 708-713.	1.9	97
101	Reward Pays the Cost of Noise Reduction in Motor and Cognitive Control. Current Biology, 2015, 25, 1707-1716.	3.9	272
102	Brain energy metabolism in early MSA-P: A phosphorus and proton magnetic resonance spectroscopy study. Parkinsonism and Related Disorders, 2015, 21, 533-535.	2.2	6
103	ADCY5 mutations are another cause of benign hereditary chorea. Neurology, 2015, 85, 80-88.	1.1	140
104	Mutations in HPCA Cause Autosomal-Recessive Primary Isolated Dystonia. American Journal of Human Genetics, 2015, 96, 657-665.	6.2	151
105	The role of cerebellum in patients with late onset cervical/segmental dystonia?â€“Evidence from the clinic. Parkinsonism and Related Disorders, 2015, 21, 1317-1322.	2.2	57
106	The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias. Parkinsonism and Related Disorders, 2015, 21, 1264-1268.	2.2	25
107	The clinical and genetic heterogeneity of paroxysmal dyskinesias. Brain, 2015, 138, 3567-3580.	7.6	129
108	Atypical Parkinsonism. Neurologic Clinics, 2015, 33, 39-56.	1.8	34

#	Article	IF	Citations
109	All in the blink of an eye: new insight into cerebellar and brainstem function in <scp>DYT</scp>1 and <scp>DYT</scp>6 dystonia. European Journal of Neurology, 2015, 22, 762-767.	3.3	38
110	Patients with scans without evidence of dopaminergic deficit: A longâ€term followâ€up study. Movement Disorders, 2014, 29, 1820-1825.	3.9	62
111	The phenotypic spectrum of DYT24 due to ANO3 mutations. Movement Disorders, 2014, 29, 928-934.	3.9	161
112	The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases. Movement Disorders, 2014, 29, 1758-1766.	3.9	286
113	Genomewide association study in cervical dystonia demonstrates possible association with sodium leak channel. Movement Disorders, 2014, 29, 245-251.	3.9	43
114	The Clinical Syndrome of Paroxysmal Exercise-Induced Dystonia: Diagnostic Outcomes and an Algorithm. Movement Disorders Clinical Practice, 2014, 1, 57-61.	1.5	100
115	Psychogenic paroxysmal movement disorders â€“ Clinical features andÂdiagnostic clues. Parkinsonism and Related Disorders, 2014, 20, 41-46.	2.2	77
116	Commentary. Movement Disorders, 2014, 29, 310-310.	3.9	0
117	Susceptibilityâ€weighted imaging changes suggesting brain iron accumulation in Huntington's disease: an epiphenomenon which causes diagnostic difficulty. European Journal of Neurology, 2014, 21, e16-7.	3.3	14
118	The entity of parkinsonism and associated lipomatosis. Neurology, 2014, 83, 1673-1674.	1.1	2
119	Parkinsonâ€™s disease in GTP cyclohydrolase 1 mutation carriers. Brain, 2014, 137, 2480-2492.	7.6	169
120	The expanding universe of disorders of the basal ganglia. Lancet, The, 2014, 384, 523-531.	13.7	155
121	Facial tremor in dystonia. Parkinsonism and Related Disorders, 2014, 20, 924-925.	2.2	10
122	Patients with rest-tremor and scans with ipsilateral dopaminergic deficit. Journal of Neurology, 2013, 260, 1132-1135.	3.6	10
123	Migraine with aura as the predominant phenotype in a family with a PRRT2 mutation. Journal of Neurology, 2013, 260, 656-660.	3.6	17
124	Dystonic opisthotonus: A â€œred flagâ€•for neurodegeneration with brain iron accumulation syndromes?. Movement Disorders, 2013, 28, 1325-1329.	3.9	39
125	Markedly asymmetric presentation in multiple system atrophy. Parkinsonism and Related Disorders, 2013, 19, 901-905.	2.2	21
126	Commentary for â€œSlowing of saccadic eye movements in sporadic Creutzfeldtâ€Jakob diseaseâ€• Movement Disorders, 2013, 28, 293-294.	3.9	0

#	Article	IF	Citations
127	Tremulous cervical dystonia is likely to be familial: Clinical characteristics of a large cohort. Parkinsonism and Related Disorders, 2013, 19, 634-638.	2.2	27
128	Functional movement disorders are not uncommon in the elderly. Movement Disorders, 2013, 28, 540-543.	3.9	40
129	Familial psychogenic movement disorders. Movement Disorders, 2013, 28, 1295-1298.	3.9	31
130	â€œAtypicalâ€•atypical parkinsonism: New genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophyâ€”A diagnostic guide. Movement Disorders, 2013, 28, 1184-1199.	3.9	167
131	Ataxia telangiectasia presenting as dopa-responsive cervical dystonia. Neurology, 2013, 81, 1148-1151.	1.1	65
132	LOWER URINARY TRACT SYMPTOMS IN FUNCTIONAL MOVEMENT DISORDERS. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.56-e2.	1.9	0
133	Atypical parkinsonism. Current Opinion in Neurology, 2013, 26, 401-405.	3.6	49
134	The differential diagnosis of Huntington's disease-like syndromes: 'red flags' for the clinician. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 650-656.	1.9	141
135	Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency. Neurology, 2012, 79, 435-441.	1.1	45
136	The non-motor syndrome of primary dystonia: clinical and pathophysiological implications. Brain, 2012, 135, 1668-1681.	7.6	246
137	Clinical pain and experimental pain sensitivity in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2012, 18, 606-608.	2.2	19
138	Dystonia with brain manganese accumulation resulting from SLC30A10 mutations: A new treatable disorder. Movement Disorders, 2012, 27, 1317-1322.	3.9	104
139	THAP1 mutations and dystonia phenotypes: Genotype phenotype correlations. Movement Disorders, 2012, 27, 1290-1294.	3.9	126
140	Mutations in ANO3 Cause Dominant Craniocervical Dystonia: Ion Channel Implicated in Pathogenesis. American Journal of Human Genetics, 2012, 91, 1041-1050.	6.2	224
141	Validation of mobile eye-tracking as novel and efficient means for differentiating progressive supranuclear palsy from Parkinson's disease. Frontiers in Behavioral Neuroscience, 2012, 6, 88.	2.0	44
142	Treatment of Focal Dystonia. Current Treatment Options in Neurology, 2012, 14, 213-229.	1.8	28
143	Psychogenic palatal tremor may be underrecognized: Reappraisal of a large series of cases. Movement Disorders, 2012, 27, 1164-1168.	3.9	126
144	Dystonia in corticobasal degeneration: A review of the literature on 404 pathologically proven cases. Movement Disorders, 2012, 27, 696-702.	3.9	119

#	Article	IF	Citations
145	A new treatable genetic disorder of manganese metabolism causing dystoniaâ€parkinsonism and cirrhosis: The â€œNewâ€Wilson's disease?. Movement Disorders, 2012, 27, 962-962.	3.9	9
146	The distinct movement disorder in antiâ€NMDA receptor encephalitis may be related to status dissociatus: A hypothesis. Movement Disorders, 2012, 27, 1360-1363.	3.9	46
147	Magnetic resonance imaging in progressive supranuclear palsy. Journal of Neurology, 2011, 258, 549-558.	3.6	44
148	Hypodipsia discriminates progressive supranuclear palsy from other parkinsonian syndromes. Movement Disorders, 2011, 26, 901-905.	3.9	3
149	AFQ056 treatment of levodopaâ€induced dyskinesias: Results of 2 randomized controlled trials. Movement Disorders, 2011, 26, 1243-1250.	3.9	162
150	Patients with idiopathic rapidâ€eyeâ€movement sleep behavior disorder show normal gastric motility assessed by the ¹³Câ€octanoate breath test. Movement Disorders, 2011, 26, 2559-2563.	3.9	26
151	Movement Disorders on YouTube â€” Caveat Spectator. New England Journal of Medicine, 2011, 365, 1160-1161.	27.0	77
152	Health-Related Quality of Life in Multiple System Atrophy and Progressive Supranuclear Palsy. Neurodegenerative Diseases, 2011, 8, 438-446.	1.4	53
153	In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: A DTI study using TBSS. Movement Disorders, 2010, 25, 1232-1238.	3.9	70
154	Rational therapeutic approaches to progressive supranuclear palsy. Brain, 2010, 133, 1578-1590.	7.6	83
155	Nigrostriatal upregulation of 5â€HT_{2A} receptors correlates with motor dysfunction in progressive supranuclear palsy. Movement Disorders, 2009, 24, 1170-1175.	3.9	13
156	Combined 1H and 31P MR spectroscopic imaging: impaired energy metabolism in severe carotid stenosis and changes upon treatment. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2009, 22, 43-52.	2.0	19
157	In vivo Evidence for Cerebral Depletion in High-Energy Phosphates in Progressive Supranuclear Palsy. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 861-870.	4.3	43
158	Shortâ€term effects of coenzyme Q₁₀ in progressive supranuclear palsy: A randomized, placeboâ€controlled trial. Movement Disorders, 2008, 23, 942-949.	3.9	135
159	Continuous Jejunal Levodopa Infusion in Patients With Advanced Parkinson Disease. Clinical Neuropharmacology, 2008, 31, 151-166.	0.7	105